News

OmniaBio Inc. Awarded Drug Establishment License (DEL) by Health Canada, Certifying Canada’s Largest Cell & Gene Therapy CDMO

HAMILTON & TORONTO ONTARIO – December 23, 2026 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License (DEL), confirming the maturity and compliance of its Good Manufacturing Practices (GMP).    Secured less than one year after opening the Hamilton, Ontario facility, the DEL solidifies OmniaBio’s position […]

OmniaBio Inc. Awarded Drug Establishment License (DEL) by Health Canada, Certifying Canada’s Largest Cell & Gene Therapy CDMO Read More »

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer

TORONTO, ONTARIO & BOSTON, MA – October 1st, 2025 – OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to treat solid tumors in

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer Read More »

Scroll to Top